UA73566C2 - Composition of defibrotide and haematopoietic factor used for increasing amount of stem cells and method for its preparation - Google Patents

Composition of defibrotide and haematopoietic factor used for increasing amount of stem cells and method for its preparation Download PDF

Info

Publication number: UA73566C2
Authority: UA; Ukraine
Prior art keywords: hematopoietic; defibrotide; progenitor cells; cells; differs
Prior art date: 2000-04-18

Application number

UA2002119177A

Other languages

English (en)

Ukrainian (uk)

Inventor

Alessandro Massimo Gianni

Carmelo Carlo Stella

Original Assignee

Gentium Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-18

Filing date

2001-10-04

Publication date

2005-08-15

2001-10-04 Application filed by Gentium Spa filed Critical Gentium Spa

2005-08-15 Publication of UA73566C2 publication Critical patent/UA73566C2/uk

Links

JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical group C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 title claims abstract description 44
229960004120 defibrotide Drugs 0.000 title claims abstract description 43
210000000130 stem cell Anatomy 0.000 title claims abstract description 25
230000003394 haemopoietic effect Effects 0.000 title claims abstract description 24
238000000034 method Methods 0.000 title claims abstract description 20
239000000203 mixture Substances 0.000 title claims description 12
238000002360 preparation method Methods 0.000 title claims description 3
210000005259 peripheral blood Anatomy 0.000 claims abstract description 14
239000011886 peripheral blood Substances 0.000 claims abstract description 14
241000124008 Mammalia Species 0.000 claims abstract description 13
230000002123 temporal effect Effects 0.000 claims abstract description 5
210000003958 hematopoietic stem cell Anatomy 0.000 claims description 25
230000004087 circulation Effects 0.000 claims description 8
239000004480 active ingredient Substances 0.000 claims description 7
230000003213 activating effect Effects 0.000 claims description 6
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
239000007864 aqueous solution Substances 0.000 claims description 2
239000002552 dosage form Substances 0.000 claims 4
210000000988 bone and bone Anatomy 0.000 claims 1
229940124531 pharmaceutical excipient Drugs 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 abstract description 2
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 abstract description 2
241000699670 Mus sp. Species 0.000 description 14
210000004027 cell Anatomy 0.000 description 12
230000004913 activation Effects 0.000 description 11
241001465754 Metazoa Species 0.000 description 7
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
230000000694 effects Effects 0.000 description 6
210000000265 leukocyte Anatomy 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 5
241000282693 Cercopithecidae Species 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
238000011282 treatment Methods 0.000 description 4
102000036693 Thrombopoietin Human genes 0.000 description 2
108010041111 Thrombopoietin Proteins 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
230000020411 cell activation Effects 0.000 description 2
230000001332 colony forming effect Effects 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000000605 extraction Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
208000009304 Acute Kidney Injury Diseases 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
101000918983 Homo sapiens Neutrophil defensin 1 Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
102100039064 Interleukin-3 Human genes 0.000 description 1
102000004890 Interleukin-8 Human genes 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
102100029494 Neutrophil defensin 1 Human genes 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
208000033626 Renal failure acute Diseases 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
201000011040 acute kidney failure Diseases 0.000 description 1
208000012998 acute renal failure Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
-1 alkali metal salt Chemical class 0.000 description 1
238000011316 allogeneic transplantation Methods 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
230000002281 colonystimulating effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
229910003460 diamond Inorganic materials 0.000 description 1
239000010432 diamond Substances 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
210000001061 forehead Anatomy 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000036449 good health Effects 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
229940096397 interleukin-8 Drugs 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001617 migratory effect Effects 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000003887 myelocyte Anatomy 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Peptides Or Proteins (AREA)

UA2002119177A 2000-04-18 2001-10-04 Composition of defibrotide and haematopoietic factor used for increasing amount of stem cells and method for its preparation UA73566C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00830293A EP1147777A1 (en)	2000-04-18	2000-04-18	Combination of defibrotide and G-CSF and its use to activate haematopoietic progenitors
PCT/EP2001/004105 WO2001078761A2 (en)	2000-04-18	2001-04-10	Mixture of defibrotide and g-csf ant its use for activating haematopoietic progenitors

Publications (1)

Publication Number	Publication Date
UA73566C2 true UA73566C2 (en)	2005-08-15

Family

ID=8175292

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2002119177A UA73566C2 (en)	2000-04-18	2001-10-04	Composition of defibrotide and haematopoietic factor used for increasing amount of stem cells and method for its preparation

Country Status (31)

Country	Link
US (1)	US20040131588A1 (xx)
EP (3)	EP1147777A1 (xx)
JP (1)	JP5205668B2 (xx)
KR (1)	KR100849491B1 (xx)
CN (1)	CN1183962C (xx)
AT (2)	ATE443524T1 (xx)
AU (2)	AU2001258322B2 (xx)
BG (1)	BG107203A (xx)
CA (1)	CA2406179C (xx)
CY (1)	CY1104971T1 (xx)
CZ (1)	CZ20023426A3 (xx)
DE (2)	DE60140015D1 (xx)
DK (2)	DK1276497T3 (xx)
EE (1)	EE200200596A (xx)
ES (2)	ES2252227T3 (xx)
HR (1)	HRP20020835A2 (xx)
HU (1)	HUP0300560A3 (xx)
IL (1)	IL152328A (xx)
IS (1)	IS2171B (xx)
MX (1)	MXPA02010346A (xx)
NO (1)	NO20024988L (xx)
NZ (1)	NZ522016A (xx)
PL (1)	PL358100A1 (xx)
PT (1)	PT1621207E (xx)
RO (1)	RO121006B1 (xx)
RU (1)	RU2248216C2 (xx)
SI (1)	SI21079B (xx)
SK (1)	SK14892002A3 (xx)
UA (1)	UA73566C2 (xx)
WO (1)	WO2001078761A2 (xx)
ZA (1)	ZA200208413B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8771663B2 (en)	2000-04-18	2014-07-08	Gentium Spa	Formulation having mobilising activity
ZA200509361B (en) *	2003-07-29	2007-03-28	Dompus Pa	Pharmaceutical combination of G-CSF and PLGF useful for blood stem cell mobilization
US20050069553A1 (en)	2003-08-13	2005-03-31	Yi Zheng	Chimeric peptides for the regulation of GTPases
WO2005017160A2 (en) *	2003-08-13	2005-02-24	Children's Hospital Medical Center	Mobilization of hematopoietic cells
EP2103689A1 (en)	2008-03-19	2009-09-23	Gentium S.p.A.	Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
RU2376985C1 (ru) *	2008-07-17	2009-12-27	Владислав Николаевич Ласкавый	Средство для активации стволовых клеток
CN103260627A (zh)	2010-11-12	2013-08-21	真蒂奥姆有限公司	去纤维蛋白多核苷酸用于预防和/或治疗移植物抗宿主病(gvhd)
KR102038357B1 (ko)	2012-06-22	2019-10-31	젠티엄 에스알엘	디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법
EP3026122A1 (en)	2014-11-27	2016-06-01	Gentium S.p.A.	Cellular-based method for determining the potency of defibrotide
CN106567694A (zh) *	2016-11-14	2017-04-19	北京国泰通源技术有限公司	智能控水短节
EP3574103A4 (en) *	2018-01-12	2020-09-23	Cellmig Biolabs Inc.	METHODS OF GENERATION OF CYTOCAPSULES AND CYTOCAPSULAR TUBES
CN114730031B (zh)	2019-11-13	2024-04-12	富士胶片株式会社	装饰膜、成型物及电子器件

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2154279A1 (de)	1970-11-03	1972-05-25	Crinos Industria Farmaco	Medikamente für das fibrinolytische System
US3899481A (en)	1970-11-03	1975-08-12	Crinos Industria Farmaco	Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs
IT1043823B (it)	1970-11-03	1980-02-29	Prephar	Procedimento per l estrazione di acidi nucleici da organi animali
IT1206341B (it)	1984-02-16	1989-04-14	Crinos Industria Farmaco	Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
US4694134A (en)	1985-05-28	1987-09-15	Ajax Magnethermic Corporation	Apparatus for overheating edges of skelp for the production of compression welded pipe
US5223609A (en) *	1986-04-17	1993-06-29	Crinos Industria Farmacobiologica S.P.A.	Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
IT1190313B (it)	1986-04-17	1988-02-16	Crinos Industria Farmaco	Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante
IT1223322B (it) *	1987-10-23	1990-09-19	Crinos Industria Farmaco	Metodo per prevenire la formazione di coaguli sanguigni nel circuito extracorporeo di apparecchi di dialisi a composizione utile per esso
JP2907447B2 (ja) *	1988-08-24	1999-06-21	中外製薬株式会社	抗血栓剤
IT1231509B (it) *	1989-09-07	1991-12-07	Crinos Industria Farmaco	Composizione farmceutica ad uso topico per la terapia della fragilita' capillare.
US5199942A (en) *	1991-06-07	1993-04-06	Immunex Corporation	Method for improving autologous transplantation
US5977083A (en) *	1991-08-21	1999-11-02	Burcoglu; Arsinur	Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
JP3021906B2 (ja) *	1992-01-28	2000-03-15	松下電器産業株式会社	電動調理機
RU2136667C1 (ru) *	1995-04-18	1999-09-10	Научно-исследовательский институт фармакологии РАМН	Производные 2-меркаптобензимидазола, обладающие противоишемической, антиаритмической и противофибрилляторной активностью
JPH08127539A (ja) *	1994-10-31	1996-05-21	Ajinomoto Co Inc	ヒトｉｌ−１１を含有する末梢血幹細胞増加剤
CA2206496A1 (en) *	1994-11-30	1996-06-06	Chugai Seiyaku Kabushiki Kaisha	Thrombocytotic factor
DE69733694T2 (de) *	1996-07-10	2006-07-06	Muramatsu, Takashi, Nagoya	Verwendung von proteinen aus der mk familie als hämatopoietischer faktor
WO1999026639A1 (en) *	1997-11-26	1999-06-03	Allegheny University Of The Health Sciences	Methods for mobilizing hematopoietic facilitating cells and hematopoietic stem cells into the peripheral blood
US6573372B2 (en) *	1999-01-07	2003-06-03	Heska Corporation	Feline immunoglobulin E molecules and compositions there of

2000
- 2000-04-18 EP EP00830293A patent/EP1147777A1/en not_active Withdrawn
2001
- 2001-04-10 PL PL01358100A patent/PL358100A1/xx not_active Application Discontinuation
- 2001-04-10 KR KR1020027013967A patent/KR100849491B1/ko not_active Expired - Fee Related
- 2001-04-10 JP JP2001576061A patent/JP5205668B2/ja not_active Expired - Fee Related
- 2001-04-10 DE DE60140015T patent/DE60140015D1/de not_active Expired - Lifetime
- 2001-04-10 SK SK1489-2002A patent/SK14892002A3/sk unknown
- 2001-04-10 AT AT05108424T patent/ATE443524T1/de active
- 2001-04-10 EP EP01931582A patent/EP1276497B1/en not_active Expired - Lifetime
- 2001-04-10 CN CNB018082025A patent/CN1183962C/zh not_active Expired - Fee Related
- 2001-04-10 DK DK01931582T patent/DK1276497T3/da active
- 2001-04-10 PT PT05108424T patent/PT1621207E/pt unknown
- 2001-04-10 WO PCT/EP2001/004105 patent/WO2001078761A2/en not_active Ceased
- 2001-04-10 IL IL152328A patent/IL152328A/en active IP Right Grant
- 2001-04-10 EP EP05108424A patent/EP1621207B1/en not_active Expired - Lifetime
- 2001-04-10 CZ CZ20023426A patent/CZ20023426A3/cs unknown
- 2001-04-10 EE EEP200200596A patent/EE200200596A/xx unknown
- 2001-04-10 ES ES01931582T patent/ES2252227T3/es not_active Expired - Lifetime
- 2001-04-10 DK DK05108424.2T patent/DK1621207T3/da active
- 2001-04-10 US US10/432,741 patent/US20040131588A1/en not_active Abandoned
- 2001-04-10 AU AU2001258322A patent/AU2001258322B2/en not_active Ceased
- 2001-04-10 AU AU5832201A patent/AU5832201A/xx active Pending
- 2001-04-10 CA CA2406179A patent/CA2406179C/en not_active Expired - Fee Related
- 2001-04-10 MX MXPA02010346A patent/MXPA02010346A/es active IP Right Grant
- 2001-04-10 AT AT01931582T patent/ATE310532T1/de active
- 2001-04-10 SI SI200120022A patent/SI21079B/sl not_active IP Right Cessation
- 2001-04-10 RU RU2002130719/15A patent/RU2248216C2/ru not_active IP Right Cessation
- 2001-04-10 RO ROA200201305A patent/RO121006B1/ro unknown
- 2001-04-10 DE DE60115222T patent/DE60115222T2/de not_active Expired - Lifetime
- 2001-04-10 ES ES05108424T patent/ES2335776T3/es not_active Expired - Lifetime
- 2001-04-10 HR HR20020835A patent/HRP20020835A2/xx not_active Application Discontinuation
- 2001-04-10 NZ NZ522016A patent/NZ522016A/en unknown
- 2001-04-10 HU HU0300560A patent/HUP0300560A3/hu unknown
- 2001-10-04 UA UA2002119177A patent/UA73566C2/uk unknown
2002
- 2002-10-14 IS IS6581A patent/IS2171B/is unknown
- 2002-10-16 NO NO20024988A patent/NO20024988L/no not_active Application Discontinuation
- 2002-10-17 ZA ZA200208413A patent/ZA200208413B/en unknown
- 2002-10-17 BG BG107203A patent/BG107203A/bg unknown
2006
- 2006-02-08 CY CY20061100179T patent/CY1104971T1/el unknown

Also Published As

Publication number	Publication date
CN1183962C (zh)	2005-01-12
PL358100A1 (en)	2004-08-09
EP1621207B1 (en)	2009-09-23
NO20024988L (no)	2002-12-02
SI21079B (sl)	2006-08-31
EE200200596A (et)	2004-04-15
ES2252227T3 (es)	2006-05-16
AU5832201A (en)	2001-10-30
ES2335776T3 (es)	2010-04-05
IS2171B (is)	2006-11-15
RU2002130719A (ru)	2004-03-27
IL152328A (en)	2009-12-24
SI21079A (sl)	2003-06-30
HUP0300560A2 (hu)	2003-06-28
SK14892002A3 (sk)	2003-06-03
AU2001258322B2 (en)	2006-03-16
JP5205668B2 (ja)	2013-06-05
DE60140015D1 (de)	2009-11-05
EP1276497A2 (en)	2003-01-22
ATE310532T1 (de)	2005-12-15
PT1621207E (pt)	2009-12-28
RO121006B1 (ro)	2006-11-30
DE60115222D1 (de)	2005-12-29
HRP20020835A2 (en)	2005-10-31
DE60115222T2 (de)	2006-08-10
KR20030010603A (ko)	2003-02-05
CA2406179A1 (en)	2001-10-25
EP1621207A3 (en)	2006-11-22
KR100849491B1 (ko)	2008-07-31
BG107203A (bg)	2003-05-30
ATE443524T1 (de)	2009-10-15
EP1621207A2 (en)	2006-02-01
EP1147777A1 (en)	2001-10-24
DK1621207T3 (da)	2010-02-01
NO20024988D0 (no)	2002-10-16
US20040131588A1 (en)	2004-07-08
HUP0300560A3 (en)	2005-07-28
EP1276497B1 (en)	2005-11-23
MXPA02010346A (es)	2004-09-06
ZA200208413B (en)	2003-10-17
DK1276497T3 (da)	2006-03-27
JP2004500437A (ja)	2004-01-08
CZ20023426A3 (cs)	2003-05-14
CN1434719A (zh)	2003-08-06
IL152328A0 (en)	2003-05-29
CA2406179C (en)	2012-03-27
IS6581A (is)	2002-10-14
RU2248216C2 (ru)	2005-03-20
CY1104971T1 (el)	2010-03-03
WO2001078761A2 (en)	2001-10-25
WO2001078761A3 (en)	2002-01-24
NZ522016A (en)	2004-10-29

Publication	Publication Date	Title
CN101448497B (zh)	2013-07-10	包含硝唑尼特、替唑尼特、或其混合物的组合物在制备治疗丙型肝炎药物中的应用
JP3919212B2 (ja)	2007-05-23	線維障害の創傷治療処置
KR20030034177A (ko)	2003-05-01	허혈성 질환 치료제
Le et al.	2011	Implant healing in experimental animal models of diabetes
UA73566C2 (en)	2005-08-15	Composition of defibrotide and haematopoietic factor used for increasing amount of stem cells and method for its preparation
US20140363394A1 (en)	2014-12-11	Formulation having mobilizing activity
JP2022502498A (ja)	2022-01-11	血液疾患の低強度治療
AU2001258322A1 (en)	2002-01-17	Formulation having mobilising activity
US20240181010A1 (en)	2024-06-06	Uses of il-12 as a replacement immunotherapeutic
EA009390B1 (ru)	2007-12-28	Плазмида, кодирующая фактор роста фибробластов, для лечения ангиогенных дефектов, ассоциированных с гиперхолестеринемией или диабетом
US20060247265A1 (en)	2006-11-02	Therapies for treating disorders of the eye
Fennelly et al.	1994	Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: A phase I trial
RU2448726C2 (ru)	2012-04-27	Содержащий g-csf агент для предупреждения и лечения диабетической периферической нейропатии
CN111249300B (zh)	2021-03-26	褪黑素联合甲钴胺在治疗糖尿病创面愈合障碍中的应用
CN107737108B (zh)	2018-06-26	一种治疗心肌梗死后心室重塑的口服药物组合物
CN112274520A (zh)	2021-01-29	瑞德西韦在制备治疗特发性肺纤维化的药物中的应用
JPWO2020092523A5 (xx)	2022-11-07
WO2020010180A1 (en)	2020-01-09	Compositions and methods for treating stroke
CN113425731B (zh)	2022-09-23	一种增效干细胞治疗心梗的药物及其应用
TWI271196B (en)	2007-01-21	CML therapy
CN114748610A (zh)	2022-07-15	骨钙素在制备抗炎药物中的应用
Shishido et al.	2023	Optimal Management of Severe Mpox in Patients with Uncontrolled HIV
JP2008503517A (ja)	2008-02-07	抗血管形成作用を有する医薬の製造のためのトリフルオロ酢酸カルシウムの使用
CN120346303A (zh)	2025-07-22	rhBMP9在制备用于治疗特发性肺纤维化相关肺动脉高压的药物中的用途
CN116036105A (zh)	2023-05-02	一种治疗淋巴水肿的药物运用